Allosteric Modulators With Basal and Stimulated Activity

Why Basal and Stimulated Activity Must Be Separated

A target can generate activity even when no agonist is present. An allosteric modulator may alter that basal activity and also alter the additional activity produced by an agonist. These effects need not have the same direction: a modulator might raise basal activity while reducing the agonist-driven increment. The net pathway input then depends on both the agonist condition and the modulator concentration.

The model here represents those two effects separately. It is an activity model, not a model of orthosteric competition: the modulator does not displace the agonist in the equations. Instead, modulator occupancy changes the activity contribution assigned to the basal and stimulated components.

An Occupancy-Based Activity Model

Assume the modulator binds reversibly to one class of target sites at equilibrium. Let \(K_M\) be its dissociation constant and \(m(C)\) the fraction of target occupied by modulator. With free modulator concentration \(C\), the one-site occupancy relation is:

This relation follows from the equilibrium definition \(K_M=[R][M]/[RM]\), where \([R]\), \([M]\), and \([RM]\) are the free target, free modulator, and modulator-bound target concentrations. Combining that definition with the target balance \([R]_{\mathrm{total}}=[R]+[RM]\) gives \(m=[RM]/[R]_{\mathrm{total}}=C/(K_M+C)\). Thus \(m=0\) at \(C=0\), \(m=0.5\) at \(C=K_M\), and occupancy approaches 1 as \(C\) becomes large.

For the agonist, assume a saturable concentration-response function with no modulator present:

Here \(K_A\) is the agonist concentration at which this function equals 0.5. The function describes the fraction of the maximum agonist-driven increment reached, not the fraction of target occupied by agonist in a detailed binding model.

Use separate factors \(\eta_B\) and \(\eta_S\) for modulator effects on the basal and stimulated components. A value of 1 means no modulation of that component; a value greater than 1 increases it, and a value between 0 and 1 decreases it. The resulting activity input is:

The first term is basal activity: unoccupied target contributes at the unmodulated level, while occupied target contributes at the level scaled by \(\eta_B\). The second term is the agonist-driven increment, scaled separately by \(\eta_S\). When \(C=0\), \(m=0\), and the model reduces to \(U(0,A)=U_b^0+E_{\max}f(A)\). With no agonist, \(A=0\), so the stimulated increment is zero and only modulated basal activity remains.

Worked Calculations

Why the Net Effect Depends on Agonist Context

Subtract the unmodulated activity \(U(0,A)\) from the activity at concentration \(C\). Because both components are linear in occupancy, the difference simplifies to:

This expression is a useful justification for evaluating the components separately. Since \(m(C)\) is nonnegative, the sign of the net change for any \(C>0\) is determined by the bracketed expression. A positive basal effect does not guarantee a positive total effect: the stimulated component may dominate in the opposite direction. At \(A=0\), \(f(A)=0\), so only the basal effect contributes. At higher agonist concentrations, the stimulated contribution becomes more influential as \(f(A)\) increases.

For fixed \(A\), the same expression also gives the concentration dependence. Differentiating the occupancy relation gives \(dm/dC=K_M/(K_M+C)^2\), and therefore:

Under this model, activity changes monotonically with \(C\) at a fixed agonist concentration: it rises if the bracket is positive, falls if it is negative, and is unchanged if it is zero. The response approaches a finite limit as occupancy approaches 1. This does not mean the same modulator must have the same net direction at every agonist concentration; the bracket can change sign with \(f(A)\).

Diagnostics, Alternatives, and Limits

A fit or prediction should be checked against measurements that can distinguish basal from stimulated effects. Measurements without agonist inform the basal component; measurements across agonist concentrations reveal changes in the stimulated component. A modulator concentration series helps assess whether the response approaches a plateau consistent with saturable occupancy. If the estimated basal effect is being inferred only from agonist-present conditions, it may be difficult to distinguish a basal shift from a change in the agonist-driven contribution.

Warning signs include a fitted effect that does not approach a plateau despite a concentration range expected to saturate occupancy, systematic residual patterns across agonist concentrations, or a direction of response that changes with modulator concentration when the fixed-agonist model predicts a monotonic change. Such patterns may indicate inadequate data, an incorrect concentration at the target, or a model that omits relevant biology. They do not by themselves identify which explanation is correct.

These approaches answer related but different questions. The model in this tutorial is a compact way to supply a modulated activity input to a pathway model; it is not a detailed account of molecular binding states. Its assumptions may fail if modulator binding changes with agonist occupancy, if the modulator changes agonist potency, if occupancy is not at equilibrium, or if downstream pathway processing is nonlinear. It also treats \(U\) as pathway input, not necessarily as a directly measured biomarker. A later pathway model may transform that input before it becomes an observable response.

A common mistake is to say, “The modulator is positive, so it must increase pathway activity.” That conclusion ignores what “positive” refers to and under which agonist condition it was assessed. In this model, positive modulation of basal activity means \(\eta_B>1\), while positive modulation of the agonist-driven increment means \(\eta_S>1\). If one is above 1 and the other below 1, the total effect depends on their magnitudes and on \(A\). Report both component effects and the resulting total in context.